<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">138</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2011-0-1-29-31</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>MAMMOLOGY. PROBLEM</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>МАММОЛОГИЯ. ПРОБЛЕМА</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Role of BRCA 1 и BRCA 2 gene mutations in the occurrence of male breast cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Роль мутации генов BRCA 1 и BRCA 2 в возникновении рака молочной железы у мужчин</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bykova</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Быкова</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vorotnikov</surname><given-names>I. K.</given-names></name><name xml:lang="ru"><surname>Воротников</surname><given-names>И. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vishnevskaya</surname><given-names>Ya. V.</given-names></name><name xml:lang="ru"><surname>Вишневская</surname><given-names>Я. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Denchik</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Денчик</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lyubchenko</surname><given-names>L. N.</given-names></name><name xml:lang="ru"><surname>Любченко</surname><given-names>Л. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>clingen@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow</institution></aff><aff><institution xml:lang="ru">НИИ клинической онкологии РОНЦ им. Н.Н. Блохина РАМН, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2011-02-25" publication-format="electronic"><day>25</day><month>02</month><year>2011</year></pub-date><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>29</fpage><lpage>31</lpage><history><date date-type="received" iso-8601-date="2014-07-25"><day>25</day><month>07</month><year>2014</year></date><date date-type="accepted" iso-8601-date="2014-07-25"><day>25</day><month>07</month><year>2014</year></date></history><permissions><copyright-year>2011</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/138">https://ojrs.abvpress.ru/ojrs/article/view/138</self-uri><abstract xml:lang="en"><p>Particular emphasis has been recently placed on the mechanisms of carcinogenesis in breast cancer (BC), including those in male BC. The paper describes the major risk factors for BC in male patients and covers the role of BRCA1 and BRCA2 gene mutations in the occurrence of this pathology. The most important studies conducted in this area and their results are presented.</p></abstract><trans-abstract xml:lang="ru"><p>В последнее время особое внимание уделяют механизмам канцерогенеза при РМЖ, в том числе и у мужчин. В статье описаны основные факторы риска развития РМЖ у пациентов мужского пола, освещена роль мутации генов BRCA 1 и BRCA 2 в возникновении данной патологии. Представлены наиболее значимые исследования, проводящиеся в этой области, и их результаты.</p></trans-abstract><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>males</kwd><kwd>BRCA1 and BRCA/2 genes</kwd><kwd>mutations</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>мужчины</kwd><kwd>гены BRCA 1 и BRCA 2</kwd><kwd>мутации</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Basham V., Lipscombe J., Word J. et al. BRCA 1 and BRCA 2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002;4:1–5.</mixed-citation><mixed-citation xml:lang="ru">Basham V., Lipscombe J., Word J. et al. BRCA 1 and BRCA 2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002;4:1–5.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Вестн РОНЦ им. Н.Н. Блохина РАМН 2010;2(Прил 1):55–6.</mixed-citation><mixed-citation xml:lang="ru">Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Вестн РОНЦ им. Н.Н. Блохина РАМН 2010;2(Прил 1):55–6.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Летягин В.П. Опухоли молочных желез у мужчин. Маммология 2006;(2):13–20.</mixed-citation><mixed-citation xml:lang="ru">Летягин В.П. Опухоли молочных желез у мужчин. Маммология 2006;(2):13–20.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Гарин А.М., Базин И.С. Десять наиболее распространенных злокачественных опухолей. М., 2006.</mixed-citation><mixed-citation xml:lang="ru">Гарин А.М., Базин И.С. Десять наиболее распространенных злокачественных опухолей. М., 2006.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Любченко Л.Н., Портной С.М., Поспе- хова Н.И. и др. Клинико-молекулярные аспекты наследственного рака молочной железы. Молекул мед 2007;(1):8–9.</mixed-citation><mixed-citation xml:lang="ru">Любченко Л.Н., Портной С.М., Поспе- хова Н.И. и др. Клинико-молекулярные аспекты наследственного рака молочной железы. Молекул мед 2007;(1):8–9.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Любченко Л.Н. Наследственный рак молочной железы и яичников: ДНК- диагностика, индивидуальный прогноз, лечение и профилактика. Автореф. дис. ... д-ра мед. наук. М., 2009.</mixed-citation><mixed-citation xml:lang="ru">Любченко Л.Н. Наследственный рак молочной железы и яичников: ДНК- диагностика, индивидуальный прогноз, лечение и профилактика. Автореф. дис. ... д-ра мед. наук. М., 2009.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Friedman L.S., Gayther S.A., Kurosaki T. et al. Mutation analysis of BRCA 1 and BRCA 2 in a male breast cancer population. Am J Human Genet 1997;60(2):313–9.</mixed-citation><mixed-citation xml:lang="ru">Friedman L.S., Gayther S.A., Kurosaki T. et al. Mutation analysis of BRCA 1 and BRCA 2 in a male breast cancer population. Am J Human Genet 1997;60(2):313–9.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Mohamad H., Apffelstaedt J. Counseling for male BRCA mutation carriers — a review. Science Direct 2008;1–10.</mixed-citation><mixed-citation xml:lang="ru">Mohamad H., Apffelstaedt J. Counseling for male BRCA mutation carriers — a review. Science Direct 2008;1–10.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Frank T.S., Deffenbaugh A.M., Reid J.E. et al. Clinical characteristics of individuals with germinel mutations in BRCA 1 and BRCA 2: analysis of 10,000 individuals. J Clin Oncol 2002;20(6):1480–90.</mixed-citation><mixed-citation xml:lang="ru">Frank T.S., Deffenbaugh A.M., Reid J.E. et al. Clinical characteristics of individuals with germinel mutations in BRCA 1 and BRCA 2: analysis of 10,000 individuals. J Clin Oncol 2002;20(6):1480–90.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Brose M.S., Rebbeck T.R., Calzone K.A. et al. Cancer risk estimates for BRCA 1 mutation carriers indetifiend in a risk evaluation program. J National Cancer Inst 2002;94(18):1365–72.</mixed-citation><mixed-citation xml:lang="ru">Brose M.S., Rebbeck T.R., Calzone K.A. et al. Cancer risk estimates for BRCA 1 mutation carriers indetifiend in a risk evaluation program. J National Cancer Inst 2002;94(18):1365–72.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Ottini L., Masala G., D’Amico C. et al. BRCA 1 and BRCA 2 mutation status and tumor characteristics in mail breast cancer: a population-based study in Italy. Cancer Res 2003;63(2):342–7.</mixed-citation><mixed-citation xml:lang="ru">Ottini L., Masala G., D’Amico C. et al. BRCA 1 and BRCA 2 mutation status and tumor characteristics in mail breast cancer: a population-based study in Italy. Cancer Res 2003;63(2):342–7.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Клиническая маммология (практическое руководство). Под ред. М.И. Давыдова и В.П. Летягина. М.: АБВ-пресс, 2010; с. 110–1.</mixed-citation><mixed-citation xml:lang="ru">Клиническая маммология (практическое руководство). Под ред. М.И. Давыдова и В.П. Летягина. М.: АБВ-пресс, 2010; с. 110–1.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
